A new supercapacitor design that uses only water, clay and graphene could source material on Mars and be more sustainable and accessible than traditional batteries

After a dismal start, the UN is hosting a "halftime summit" about its 15-year plan to meet a series of human-development targets by 2030. Delegates will try to focus on problems like extreme poverty and gender equality while watching for sparks between the representatives of Ukraine and Russia.

Ransomeware attacks against health care organizations are happening at an alarmingly high rate in 2024, putting patient health at risk.

I started work on it around a year ago on a whim because I was reading a lot of game design articles and couldn’t resist the idea of a small platform game. It’s really expanded a lot beyond that though! I’d like to start showing it to and discussing it with more people as I […]

Former Education Secretary Betsy DeVos discusses what a second Trump term could mean for U.S. education on "The Story with Martha MacCallum."

'AGT' returned on Tuesday with live shows from Universal Studios Hollywood.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

With the vision of a billion developers, AI is evolving from a specialized tool to a platform that democratizes coding. As AI’s

The post Preparing for a Billion Developers appeared first on Gigaom.

A Brief History of DevOps To understand the future of DevOps, it’s worth understanding its past—which I can recall with a level

The post DevOps, LLMs, and the Software Development Singularity appeared first on Gigaom.

It didn't take long to see what makes 16-year-old Shola Jimoh a prospect for Canada's men's soccer team. In a frenzied training session on Wednesday, he was always on the attack, always on the balls of his feet, leaving coach Jesse Marsch impressed.

Hello gentle readers, and welcome to the SwitchArcade Round-Up for August 20th, 2024. In today’s article, I’ve got a couple …

Continue reading "SwitchArcade Round-Up: Reviews Featuring ‘Sam & Max: The Devil’s Playhouse’, Plus the Latest Releases and Sales"

Playtonic Friends just announced that Victory Heat Rally from developer Skydevilpalm is coming to mobile through Crunchyroll and also on …

Continue reading "‘Victory Heat Rally’ From Skydevilpalm and Playtonic Friends Is Coming to PC and Crunchyroll for Mobile on October 3rd"

Following developer TRAGsoft bringing monster collecting game Coromon to mobile after it debuted on PC and Switch, we are getting …

Continue reading "Roguelite ‘Coromon: Rogue Planet’ in Development for Release on iOS, Android, Switch, and Steam in 2025"

Sacramento-based Zennify, a tech consulting firm for financial service companies, has acquired Terazo, a digital engineering firm based in Richmond, Virginia.

The free virtual event is hosted by SolluCIO Partners, a Seattle-based company with a presence in Hawaii.

Top Democrats on Tuesday evening filed a compromise economic development bill containing state support for the life sciences and climate technology industries, ticket sales regulations, a new live theater tax credit, educator diversity reforms and more.

Getting outside – without your phone – is one way to disconnect.

A dome-shaped device floating in Halifax’s Northwest Arm could easily be confused with a buoy, but it is actually a contraption meant to turn ocean water into fresh water. Two Dalhousie University researchers hope it can help with water scarcity in the real world.

Fujifilm is developing a medium-format, 102-megapixel cinema camera, the company said in a surprise announcement. Due next year, the GFX Eterna will carry a boxy, modular design reminiscent of Sony's FX6 or the new Blackmagic Pyxis and will likely be launched with a top handle, electronic viewfinder and other optional accessories.

The new camera will have a medium format GFX 102-megapixel (MP) CMOS II HS sensor, the same one used on the GFX100 II. That sensor is 43.8mm x 32.9 mm in size, or 1.7 times larger than the full-frame sensor found on the aforementioned FX or Pyxis. That will be one of the largest cinema camera sensors available, even bigger than RED's V-Raptor XL sensor.

The benefits will be extra dynamic range, potentially high resolution and a very shallow depth of field that should allow for cinematic shots when paired with the right lens. That does bring up the fact that Fujifilm currently has no GFX glass designed specifically for film production. However, the company said it's developing a 32-90mm power zoom lens (24-70mm full-frame equivalent) and will have a mount adapter for GFX to PL lenses, which are widely used in cinema. 

One other concern might be rolling shutter distortion. RED's V-Raptor XL uses a global shutter that has zero distortion, but the sensor Fujifilm will employ has a fair bit of it . In addition, the GFX100 II captures 8K with a 1.53x crop, negating many of the benefits of a medium format sensor — so, hopefully Fujifilm will resolve those issues with its cinema camera. 

Fujifilm will show off the GFX Eterna starting tomorrow at the InterBEE 2024 media exhibition in Chiba City, Japan. It's set to be released sometime in 2025, with an exact date and pricing yet to be announced.

This article originally appeared on Engadget at https://www.engadget.com/cameras/fujifilm-is-developing-a-102mp-medium-format-cinema-camera-130027537.html?src=rss

Voyez ce que l’ancien défenseur avait à dire sur son passage dans la Belle Province!

Un défenseur bélarusse au potentiel incalculable réalise bien malgré lui les défis quotidiens qui accompagnent son physique hors-norme.

Non aux rencontres amoureuses, au sexe, au mariage ou à élever des enfants avec un homme.

In an effort to strengthen the regulatory activities for medical devices in the country, the Union health ministry has framed and finalised rules regulating the method of recruitment to various posts under the Central

The Department of Pharmaceuticals (DoP) has released the operational guidelines for the newly announced central sector scheme for Strengthening of Medical Device Industry (SMDI), aiming at providing

The centrally sponsored scheme for strengthening of medical devices industry (SMDI), launched by the Central government last week, was widely welcomed by the medical devices industry in the country.

Dr Euan McBrearty, head of commerical & innovation, Wideblue shares five steps to successful medical device development.

When chemist Dora Richardson’s employer decided to terminate the breast cancer research on the drug Tamoxifen in the early 1970s, she and her colleagues continued the work in secret.

<p> <b>Abstract</b><br />CinnaGen, the largest biopharmaceutical company in the MENA region, is a leader in developing follow-on biologicals/biosimilars. Dr&nbsp;Haleh Hamedifar, Chairperson of CinnaGen, spoke to GaBI<i>&nbsp;</i>(Generics and Biosimilars Initiative) about the company’s strategic focus, which includes expanding its product portfolio, entering highly regulated global markets, and advancing affordable treatments for conditions such as multiple sclerosis and&nbsp;immunological diseases—transforming healthcare in underserved regions.</p><p><b>Keywords</b>: Biosimilars, clinical development, commercialization, MENA</p>

This new 10-minute TEDMED talk is getting quite a bit of attention:


 (if embedded video does not work, try the TED site itself.)

In it, Roger Stein claims to have created an approach to advancing drugs through clinical trials that will "fundamentally change the way research for cancer and lots of other things gets done".

Because the costs of bringing a drug to market are so high, time from discovery to marketing is so long, and the chances of success of any individual drug are so grim, betting on any individual drug is foolish, according to Stein. Instead, risks for a large number of potential assets should be pooled, with the eventual winners paying for the losers.

To do this, Stein proposes what he calls a "megafund" - a large collection of assets (candidate therapies). Through some modeling and simulations, Stein suggests some of the qualities of an ideal megafund: it would need in the neighborhood of $3-15 billion to acquire and manage 80-150 drugs. A fund of this size and with these assets would be able to provide an equity yield of about 12%, which would be "right in the investment sweet spot of pension funds and 401(k) plans".

Here's what I find striking about those numbers: let's compare Stein's Megafund to everyone's favorite Megalosaurus, the old-fashioned Big Pharma dinosaur sometimes known as Pfizer:

	Megafund (Stein)	Megalosaurus (Pfizer)
Funding	$3-15 billion	$9 billion estimated 2013 R&D spend
Assets	80-150	81 (in pipeline, plus many more in preclinical)
Return on Equity	12% (estimated)	9.2% (last 10 years) to 13.2% (last 5)

Since Pfizer's a dinosaur, it can't possibly compete with the sleek, modern Megafund, right? Right?

These numbers look remarkably similar. Pfizer - and a number of its peers - are spending Megafund-sized budget each year to shepherd through a Megafund-sized number of compounds. (Note many of Pfizer's peers have substantially fewer drugs in their published pipelines, but they own many times more compounds - the pipeline is just the drugs what they've elected to file an IND on.)

What am I missing here? I understand that a fund is not a company, and there may be some benefits to decoupling asset management decisions from actual operations, but this won't be a tremendous gain, and would presumably be at least partially offset by increased transaction costs (Megafund has to source, contract, manage, and audit vendors to design and run all its trials, after all, and I don't know why I'd think it could do that any more cheaply than Big Pharma can). And having a giant drug pipeline's go/no go decisions made by "financial engineers" rather than pharma industry folks would seem like a scenario that's only really seen as an upgrade by the financial engineers themselves.
A tweet from V.S. Schulz pointed me to a post on Derek Lowe's In the Pipeline blog. which lead to a link to this paper by Stein and 2 others in Nature Biotechnology from a year and a half ago. The authors spend most of their time differentiating themselves from other structures in the technical, financial details rather than explaining why megafund would work better at finding new drugs. However, they definitely think this is qualitatively different from existing pharma companies, and offer a couple reasons. First,

[D]ebt financing can be structured to be more “patient” than private or public equity by specifying longer maturities; 10- to 20-year maturities are not atypical for corporate bonds. ... Such long horizons contrast sharply with the considerably shorter horizons of venture capitalists, and the even shorter quarterly earnings cycle and intra-daily price fluctuations faced by public companies.

I'm not sure where this line of though is coming from. Certainly all big pharma companies' plans extend decades into the future - there may be quarterly earnings reports to file, but that's a force exerted far more on sales and marketing teams than on drug development. The financing of pharmaceutical development is already extremely long term.

Even in the venture-backed world, Stein and team are wrong if they believe there is pervasive pressure to magically deliver drugs in record time. Investors and biotech management are both keenly aware of the tradeoffs between speed and regulatory success. Even this week's came-from-nowhere Cinderella story, Intercept Pharmaceuticals, was founded with venture money over a decade ago - these "longer maturities" are standard issue in biotech. We aren't making iPhone apps here, guys.

Second,

Although big pharma companies are central to the later stages of drug development and the marketing and distributing of approved drugs, they do not currently play as active a role at the riskier preclinical and early stages of development

Again, I'm unsure why this is supposed to be so. Of Pfizer's 81 pipeline compounds, 55 are in Phase 1 or 2 - a ratio that's pretty heavy on early, risky project, and that's not too different from industry as a whole. Pfizer does not publish data on the number of compounds it currently has undergoing preclinical testing, but there's no clear reason I can think of to assume it's a small number.

So, is Megafund truly a revolutionary idea, or is it basically a mathematical deck-chair-rearrangement for the "efficiencies of scale" behemoths we've already got?

[Image: the world's first known dino, Megalosaurus, via Wikipedia.]

Blood pressure is one of the critical vital signs for health, but standard practice can only capture a snapshot, using a pressure cuff to squeeze arteries. Continuous readings are available, but only by inserting a transducer directly into an artery via a needle and catheter. Thanks to researchers at Caltech, however, it may soon be possible to measure blood pressure continuously at just about any part of the body.

In a paper published in July in PNAS Nexus, the researchers describe their resonance sonomanometry (RSM) approach to reading blood pressure. This new technology uses ultrasound to measure the dimensions of artery walls. It also uses sound waves to find resonant frequencies that can reveal the pressure within those walls via arterial wall tension. This information is sufficient to calculate the absolute pressure within the artery at any moment, without the need for calibration.

This last factor is important, as other non-invasive approaches only provide relative changes in blood pressure. They require periodic calibration using readings from a traditional pressure cuff. The RSM technology eliminates the need for calibration, making continuous readings more reliable.

How resonance sonomanometry works

The researchers’ RSM system uses an ultrasound transducer to measure the dimensions of the artery. It also transmits sound waves at different frequencies. The vibrations cause the arterial walls to move in and out in response, creating a distinct pattern of motion. When the resonant frequency is transmitted, the top and bottom of the artery will move in and out in unison.

This resonant frequency can be used to determine the tension of the artery walls. The tension in the walls is directly correlated with the fluid pressure of the blood within the artery. As a result, the blood pressure can be calculated at any instant based on the dimensions of the artery and its resonant frequency.

The researchers have validated this approach with both mockups and human subjects. They first tested the technology on an arterial model that used a thin-walled rubber tubing and a syringe to vary the pressure. They tested this mockup using multiple pressures and tubing of different diameters.

The researchers then took measurements with human subjects at their carotid arteries (located in the neck), using a standard pressure cuff to take intermittent measurements. The RSM technology was successful, and subsequently was also demonstrated on axillary (shoulder), brachial (arm), and femoral (leg) arteries. The readings were so clear that the researchers mention that they might even be able to detect blood pressure changes related to respiration and its impact on thoracic pressure.

Unlike traditional pressure cuff approaches, RSM provides data during the entire heartbeat cycle, and not just the systolic and diastolic extremes (In other words, the two numbers you receive during a traditional blood pressure measurement). And the fact that RSM works with different-sized arteries means that it should be applicable across different body sizes and types. Using ultrasound also eliminates possible complications such as skin coloration that can affect light-based devices.

The researchers tested their ultrasound-based blood pressure approach on subjects’ carotid arteries.Esperto Medical

“I’m a big fan of continuous monitoring; a yearly blood pressure reading in the doctor’s office is insufficient for decision making,” says Nick van Terheyden, M.D., the digital health leader with Iodine Software, a company providing machine learning technologies to improve healthcare insights. “A new approach based on good old rules of math and physics is an exciting development.”

The Caltech researchers have created a spinoff company, Esperto Medical, to develop a commercial product using RSM technology. The company has created a transducer module that is smaller than a deck of cards, making it practical to incorporate into a wearable armband. They hope to miniaturize the hardware to the point that it could be incorporated into a wrist-worn device. According to Raymond Jimenez, Esperto Medical’s chief technology officer, “this technology poses the potential to unlock accurate, calibration-free [blood pressure measurements] everywhere—in the clinic, at the gym, and even at home.”

It appears that there’s a significant market for such a product. “92 percent of consumers who intend to buy a wearable device are willing to pay extra for a health-related feature, and blood pressure ranks first among such features,” says Elizabeth Parks, the president of Internet of Things consulting firm Parks Associates.

In the future, rather than relying on arm-squeezing blood pressure cuffs, smart watches may be able to directly monitor blood pressure throughout the day, just as they already do for heart rate and other vital signs.

Neuralink’s visual prosthesis Blindsight has been designated a breakthrough device by the U.S. Food and Drug Administration, which potentially sets the technology on a fast track to approval.

In confirming the news, an FDA spokesperson emphasized that the designation does not mean that Blindsight is yet considered safe or effective. Technologies in the program have potential to improve the current standard of care and are novel compared to what’s available on the market, but the devices still have to go through full clinical trials before seeking FDA approval.

Still, the announcement is a sign that Neuralink is moving closer to testing Blindsight in human patients. The company is recruiting people with vision loss for studies in the United States, Canada, and the United Kingdom.

Visual prostheses work by capturing visual information with a video camera, typically attached to glasses or a headset. Then a processor converts the data to an electrical signal that can be relayed to the nervous system. Retinal implants have been a common approach, with electrodes feeding the signal to nerves in the retina, at the back of the eye, from where it travels on to the brain. But Blindsight uses a brain implant to send the signal directly to neurons in the visual cortex.

In recent years, other companies developing artificial vision prosthetics have reached clinical research trials or beyond, only to struggle financially, leaving patients without support. Some of these technologies live on with new backing: Second Sight’s Orion cortical implant project is now in a clinical trial with Cortigent, and Pixium Vision’s Prima system is now owned by Science, with ex-Neuralink founder Max Hodak at the helm. No company has yet commercialized a visual prosthetic that uses a brain implant.

Elon Musk’s Claims About Blindsight

Very little information about Blindsight is publicly available. As of this writing, there is no official Blindsight page on the Neuralink website, and Neuralink did not respond to requests for comment. It’s also unclear how exactly Blindsight relates to a brain-computer interface that Neuralink has already implanted in two people with paralysis, who use their devices to control computer cursors.

Experts who spoke with IEEE Spectrum felt that, if judged against the strong claims made by Neuralink’s billionaire co-founder Elon Musk, Blindsight will almost certainly disappoint. However, some were still open to the possibility that Neuralink could successfully bring a device to market that can help people with vision loss, albeit with less dramatic effects on their sense of sight. While Musk’s personal fortune could help Blindsight weather difficulties that would end other projects, experts did not feel it was a guarantee of success.

After Neuralink announced on X (formerly Twitter) that Blindsight had received the breakthrough device designation, Musk wrote:

The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.

Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.

To set expectations correctly, the vision will be at first be [sic] low resolution, like Atari graphics, but eventually it has the potential be [sic] better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths, like Geordi La Forge.

Musk included a picture of La Forge, a character from the science-fiction franchise Star Trek who wears a vision-enhancing visor.

Experts Puncture the Blindsight Hype

“[Musk] will build the best cortical implant we can build with current technology. It will not produce anything like normal vision. [Yet] it might produce vision that can transform the lives of blind people,” said Ione Fine, a computational neuroscientist at the University of Washington, who has written about the potential limitations of cortical implants, given the complexity of the human visual system. Fine previously worked for the company Second Sight.

A successful visual prosthetic might more realistically be thought of as assistive technology than a cure for blindness. “At best, we’re talking about something that’s augmentative to a cane and a guide dog; not something that replaces a cane and a guide dog,” said Philip Troyk, a biomedical engineer at the Illinois Institute of Technology.

Restoring natural vision is beyond the reach of today’s technology. But among Musks recent claims, Troyk says that a form of infrared sensing is plausible and has already been tested with one of his patients, who used it for help locating people within a room. That patient has a 400-electrode device implanted in the visual cortex as part of a collaborative research effort called the Intracortical Visual Prosthesis Project (ICVP). By comparison, Blindsight may have more than 1,000 electrodes, if it’s a similar device to Neuralink’s brain-computer interface.

Experts say they’d like more information about Neuralink’s visual prosthetic. “I’m leery about the fact that they are very superficial in their description of the devices,” said Gislin Dagnelie, a vision scientist at Johns Hopkins University who has been involved in multiple clinical trials for vision prosthetics, including a Second Sight retinal implant, and who is currently collaborating on the ICVP. “There’s no clear evaluation or pre-clinical work that has been published,” says Dagnelie. “It’s all based on: ‘Trust us, we’re Neuralink.’”

In the short term, too much hype could mislead clinical trial participants. It could also degrade interest in small but meaningful advancements in visual prosthetics. “Some of the [Neuralink] technology is exciting, and has potential,” said Troyk. “The way the messaging is being done detracts from that, potentially.”

After four years of negotiations, European lawmakers agreed on June 15 on a new EU Medical Devices Regulation (MDR). The MDR is the equivalent to the FDA’s CDRH regulations in the United States and essentially specifies the applicable rules when importing medical devices into Europe, which is the world’s second-largest device market. Rules relate, for...… Continue Reading

Aug 31, 2016

As the African Union develops its long-term agenda 2063 for the continent, science, technology and innovation will play a bigger part in development goal setting, especially in the context of social and economic growth.

Dec 13, 2016

"Unlike the digital revolution that relied on pre-existing technologies, the new bioeconomy will involve more local research, teaching and commercialization. This will require greater involvement of local universities, especially those with an entrepreneurial inclination."

Apr 12, 2024

Judd Devermont is interviewed by Natalie Colber about the U.S.'s new policy towards sub-Saharan Africa in April, 2024.

Jul 8, 2024

The July 2024 update to our database on the U.S. government investments in energy research, development, demonstration, and deployment (ERD3) through the U.S. Department of Energy.

Apr 11, 2024

On April 9, the study group met for the third time to examine economic development in Africa. The group explored connections between politics and economic growth trajectories across the continent, and analyzed the role of political instability and policy decisions in fostering development. Discussions covered the impact of factors like commodity markets, foreign aid, trade deals, and regional integration initiatives on development indicators. The study group counted with the presence of external expert guest H.E. Patrick Achi, former Prime Minister of Côte d’Ivoire. Prime Minister Achi shared about his experience at the highest level of government and presented the story of Côte d’Ivoire’s post-independence development as a microcosm of the broader challenges and opportunities facing African nations.

Apr 17, 2024

Meghan O’Sullivan, Harvard University’s Belfer Center for Science and International Affairs director and former Deputy National Security Advisor, joins 'Squawk Box' to discuss the latest developments in the Middle East conflict, the potential impact of new sanctions on Iran, what a possible retaliatory strikes from Israel could look like, and more.

Get mortgage help. This is why. MakingHomeAffordable.gov :60

Smartphones hold increasing amounts of sensitive personal data, so every device is now a mixed-use device. As a result, businesses must protect employee privacy as fiercely as corporate security.

The Asbury Park Waterfront

Mitch Eitel discusses shareholder activism and post-financial crisis enforcement issues

Volvo HoloLens

Volvo Cars and Ericsson developing intelligent media streaming for self-driving cars

Global - No child should die of diabetes

Artistry Men� New Products

Eyeglass World launches first retail collection of smart glass technologies in the U.S., including specially designed prescription lens options and hardware for Recon, Vuzix and Epson wearable devices.

Atrial Fibrillation affects your heart, but it can also affect your mind. The risk of stroke is five times higher in those with AFib. Learn more and take an online AFib risk assessment at MyAFib.org (1)

A Technology Development Story: meet the SYNERGY� Stent System engineers